FierceBiotech 2026-01-05 Zenas' stock sinks in wake of autoimmune phase 3 data despite primary endpoint hit
FierceBiotech 2026-01-05 Abbott launches AI-based Libre Assist, its new in-app feature for meal planning
FierceBiotech 2026-01-05 Insilico, fresh off its Hong Kong IPO, pens potential $888M cancer R&D pact with Servier
FierceBiotech 2026-01-02 Cellular energy booster restores cognition in mice with advanced Alzheimer’s disease
FierceBiotech 2026-01-02 NIH instability grows with exit of neuro director, leaving half of institutes under interim leadership
FierceBiotech 2026-01-02 Sanofi, Corcept surprised by FDA rejections for MS, Cushing's syndrome drugs
FierceBiotech 2026-01-02 Neuralink to kick-start 'high-volume production' of brain-computer interface devices, Elon Musk says
FierceBiotech 2026-01-02 Neuro biotech Nido closes after phase 2 study fails to move needle in rare disease
FierceBiotech 2026-01-02 AbbVie, Gilead gift themselves clinical-stage cancer drugs via licensing deals
FierceBiotech 2026-01-02 Biohaven flunks phase 2 depression trial, adding to concerns for pivotal epilepsy readout
FierceBiotech 2026-01-02 Ultragenyx plans major cost-cutting push after flunking phase 3 brittle bone trials
FierceBiotech 2025-12-31 Quanterix's blood test for Alzheimer's disease uncovers potentially treatable population in decades-long study
FierceBiotech 2025-12-30 Breast cancer tops list of most-studied diseases for 5th year in a row: report